FOXO4-DRI is a synthetic peptide designed to eliminate senescent cells by disrupting the interaction between FOXO4 and p53 proteins. It is typically administered via daily subcutaneous injections, with dosages ranging from 250 mcg to 500 mcg over a cycle of 8 to 16 weeks.
- Selectively eliminates senescent cells.
- Dosage gradually increases from 250 mcg to 500 mcg.
- Reconstitute with 3 mL bacteriostatic water for a ~3.33 mg/mL concentration.
- Injection technique involves subcutaneous administration with site rotation.
- No human clinical safety or efficacy data currently exist.
Reconstitution
Vial strength
10 mg
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
1 unit = 0.01 mL = 33.3 mcg on a U-100 insulin syringe
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl/roll until dissolved (do not shake).
- 4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1-4 | 250 mcg | 7.5 units (0.075 mL) |
| Weeks 5-8 | 375 mcg | 11 units (0.11 mL) |
| Weeks 9-16 | 500 mcg | 15 units (0.15 mL) |
Protocol detail
| Start | 250 mcg daily for the first 4 weeks; increase gradually as tolerated. |
|---|---|
| Mid-Phase | 375 mcg daily during Weeks 5–8. |
| Target | 500 mcg daily by Weeks 9–16. |
| Frequency | Once per day (subcutaneous). |
| Cycle Length | 8–16 weeks; longer cycles may use intermittent dosing schedules as tolerated. |
| Timing | Any consistent time; rotate injection sites to minimize local irritation. |
Overview at a glance
| Goal | Selectively clear senescent cells via disruption of FOXO4–p53 binding. |
|---|---|
| Schedule | Daily subcutaneous injections for 8–16 weeks with gradual dose escalation. |
| Dose Range | 250–500 mcg daily; starting low and titrating upward over time. |
| Reconstitution | 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements. |
| Storage | Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw. |
How it works
FOXO4-DRI is a synthetic peptide that targets and eliminates senescent cells by interfering with the FOXO4–p53 protein interaction. In healthy cells, FOXO4 sequesters p53 in the nucleus. However, in senescent cells, FOXO4-DRI causes p53 to move to the mitochondria, triggering programmed cell death specifically in these aged, dysfunctional cells while sparing healthy ones. This mechanism leads to a reduction in senescent cell burden, improving tissue function and mitigating age-related pathologies, as observed in animal studies.
Reported effects
- Promotes selective clearance of senescent cells in various tissues.
- Animal studies show improvements in tissue regeneration and reduced inflammation.
- Enhanced organ function following senescent cell clearance in preclinical models.
- Improved testosterone levels and cellular health markers in aged mice.
Reported side effects
- No human clinical safety or efficacy data currently exist.
- Tolerability in humans remains uncharacterized.
- Injection-site reactions (mild redness, irritation) may occur.
Storage
Lyophilised (unmixed)
Freeze at -20 °C (-4 °F) or below in dry, dark conditions; minimize moisture exposure.
After reconstitution
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1 month when using bacteriostatic water. Avoid freeze-thaw cycles.
Supplies
| Peptide vials (10 mg each) | Approximately 3-5 vials for an 8-16 week protocol. |
|---|---|
| Insulin Syringes (U-100) | Approximately 56-112 syringes for an 8-16 week protocol (7 per week). |
| Bacteriostatic Water (10 mL bottles) | 1-2 bottles for an 8-16 week protocol. |
| Alcohol Swabs | Approximately 2-3 boxes of 100-count for an 8-16 week protocol (14 per week). |
Important notes
- Use new sterile insulin syringes (typically 29–31 gauge, 0.5 inch needle) for each injection.
- Rotate injection sites (abdomen, thighs, upper arms) at least 1 inch apart.
- Clean the injection site with an alcohol swab and allow to dry before injecting.
- Inject slowly and steadily; no need to aspirate for subcutaneous injections.
- Document daily dose and site rotation.
Frequently asked questions
What is the primary function of FOXO4-DRI?
FOXO4-DRI is designed to selectively induce apoptosis (programmed cell death) in senescent cells by disrupting a specific protein interaction, thereby clearing these 'zombie' cells from the body.
How is FOXO4-DRI typically administered?
It is administered via subcutaneous injection, usually once daily, with the injection site rotated to prevent irritation.
What is the recommended reconstitution for a 10 mg vial of FOXO4-DRI?
For a 10 mg vial, it is recommended to reconstitute with 3.0 mL of bacteriostatic water, resulting in a concentration of approximately 3.33 mg/mL, which facilitates easy dose measurement with an insulin syringe.
Are there any human studies on FOXO4-DRI?
Currently, there are no human clinical safety or efficacy data available for FOXO4-DRI. All reported benefits and side effects are based on preclinical animal studies.
Educational reference only. These figures summarise how FOXO4-DRI is commonly described in research literature and supplier documentation, including the FOXO4-DRI listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
Livagen (20 mg Vial)
Synthetic tetrapeptide that may support cellular health and regeneration in aging tissues.
NAD+ (500 mg Vial)
Fuel cellular energy, enhance DNA repair, support mitochondrial health.
CJC-1295 DAC (2 mg Vial)
Long-acting GHRH analog for sustained growth hormone release.
CJC-1295 NO DAC (5 mg Vial)
Stimulates natural growth hormone release for improved body composition and recovery.